{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:11:44Z","timestamp":1777990304593,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015831","name":"Radius Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40273-023-01270-x","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T12:01:50Z","timestamp":1682164910000},"page":"819-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-Effectiveness of Sequential Abaloparatide\/Alendronate in Men at High Risk of Fractures in the United States"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea J.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leny","family":"Pearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Caminis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"issue":"3","key":"1270_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res. 2007;22(3):465\u201375.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1270_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82.","journal-title":"Arch Osteoporos"},{"issue":"12","key":"1270_CR3","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/jbmr.4719","volume":"37","author":"E Czerwinski","year":"2022","unstructured":"Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, et al. The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial. J Bone Miner Res. 2022;37(12):2435\u201344.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1270_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019;49(2):184\u201396.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1270_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother. 2019;53(2):134\u201343.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1270_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum. 2020;50(3):394\u2013400.","journal-title":"Semin Arthritis Rheum"},{"key":"1270_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01239-2","author":"N Li","year":"2023","unstructured":"Li N, Beaudart C, Cauley JA, Ing SW, Lane NE, Reginster JY, et al. Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review. Pharmacoeconomics. 2023. https:\/\/doi.org\/10.1007\/s40273-022-01239-2.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1270_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, et al. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int. 2019;30(1):45\u201357.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1270_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1270_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"1270_CR11","doi-asserted-by":"crossref","unstructured":"Academy of Managed Care Pharmacy. AMCP format for formulary submissions: guidance on submission of pre-approval and post-approval clinical and economic information and evidence, Version 4.1. 2020. https:\/\/www.amcp.org\/Resource-Center\/format-formulary-submissions\/AMCP-Format-for-Formulary-Submissions-4.1. Accessed 14 Apr 2023.","DOI":"10.18553\/jmcp.2024.30.4-b.s1"},{"issue":"5","key":"1270_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","volume":"12","author":"M Hiligsmann","year":"2009","unstructured":"Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12(5):687\u201396.","journal-title":"Value Health"},{"issue":"3","key":"1270_CR13","first-page":"334","volume":"26","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Reginster JY, Silverman S. The value of a patient-level modeling approach and need for better reporting in economic evaluations of osteoporosis. J Manag Care Spec Pharm. 2020;26(3):334\u20135.","journal-title":"J Manag Care Spec Pharm"},{"key":"1270_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115286","volume":"134","author":"E Soreskog","year":"2020","unstructured":"Soreskog E, Strom O, Spangeus A, Akesson KE, Borgstrom F, Banefelt J, et al. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. 2020;134: 115286.","journal-title":"Bone"},{"issue":"6","key":"1270_CR15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00198-020-05769-3","volume":"32","author":"O Tran","year":"2021","unstructured":"Tran O, Silverman S, Xu X, Bonafede M, Fox K, McDermott M, et al. Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women. Osteoporos Int. 2021;32(6):1195\u2013205.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1270_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","volume":"21","author":"B Ettinger","year":"2010","unstructured":"Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd. Updated fracture incidence rates for the US version of FRAX. Osteoporos Int. 2010;21(1):25\u201333.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1270_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40618-022-01910-7","volume":"46","author":"C Luo","year":"2023","unstructured":"Luo C, Qin SX, Wang QY, Li YF, Qu XL, Yue C, et al. Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. J Endocrinol Investig. 2023;46(2):367\u201379.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"1270_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00198-021-06010-5","volume":"33","author":"S Nayak","year":"2022","unstructured":"Nayak S, Greenspan SL. Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis. Osteoporos Int. 2022;33(1):229\u201338.","journal-title":"Osteoporos Int"},{"issue":"7","key":"1270_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00198-020-05334-y","volume":"31","author":"EM Lewiecki","year":"2020","unstructured":"Lewiecki EM, Chastek B, Sundquist K, Williams SA, Weiss RJ, Wang Y, et al. Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. Osteoporos Int. 2020;31(7):1299\u2013304.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1270_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","volume":"27","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27(5):585\u201390.","journal-title":"Bone"},{"issue":"4","key":"1270_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jocd.2013.08.001","volume":"16","author":"NB Watts","year":"2013","unstructured":"Watts NB, Leslie WD, Foldes AJ, Miller PD. International Society for Clinical Densitometry Position Development Conference: task force on normative databases. J Clin Densitom. 2013;16(4):472\u201381.","journal-title":"J Clin Densitom"},{"issue":"5","key":"1270_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8(5):468\u201389.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1270_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jama.297.4.387","volume":"297","author":"JR Center","year":"2007","unstructured":"Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387\u201394.","journal-title":"JAMA"},{"issue":"10","key":"1270_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29(10):895\u2013911.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1270_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/jbmr.3118","volume":"32","author":"T Tran","year":"2017","unstructured":"Tran T, Bliuc D, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Population-wide impact of non-hip non-vertebral fractures on mortality. J Bone Miner Res. 2017;32(9):1802\u201310.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1270_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15(2):108\u201312.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1270_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003;32(5):468\u201373.","journal-title":"Bone"},{"issue":"5","key":"1270_CR28","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.37765\/ajmc.2020.43156","volume":"26","author":"SA Williams","year":"2020","unstructured":"Williams SA, Chastek B, Sundquist K, Barrera-Sierra S, Leader D Jr, Weiss RJ, et al. Economic burden of osteoporotic fractures in US managed care enrollees. Am J Manag Care. 2020;26(5):e142\u20139.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1270_CR29","first-page":"461","volume":"23","author":"J Weaver","year":"2017","unstructured":"Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P. Prevalence and cost of subsequent fractures among US patients with an incident fracture. J Manag Care Spec Pharm. 2017;23(4):461\u201371.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"1270_CR30","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00198-022-06460-5","volume":"33","author":"J Talevski","year":"2022","unstructured":"Talevski J, Sanders KM, Lal A, Watts JJ, Beauchamp A, Duque G, et al. A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Osteoporos Int. 2022;33(9):1895\u2013907.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1270_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26(4):391\u2013400.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1270_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/21556660.2019.1677674","volume":"8","author":"T Gold","year":"2019","unstructured":"Gold T, Williams SA, Weiss RJ, Wang Y, Watkins C, Carroll J, et al. Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey. J Drug Assess. 2019;8(1):175\u201383.","journal-title":"J Drug Assess"},{"issue":"3","key":"1270_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","volume":"29","author":"A Svedbom","year":"2018","unstructured":"Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML, et al. Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures: results from the ICUROS. Osteoporos Int. 2018;29(3):557\u201366.","journal-title":"Osteoporos Int"},{"issue":"8","key":"1270_CR34","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Oden A, Harvey NC, Gudnason V, Sanders KM, et al. Characteristics of recurrent fractures. Osteoporos Int. 2018;29(8):1747\u201357.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1270_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00198-021-06058-3","volume":"33","author":"J Talevski","year":"2022","unstructured":"Talevski J, Sanders KM, Watts JJ, Nicholson GC, Seeman E, Iuliano S, et al. Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int. 2022;33(1):67\u201375.","journal-title":"Osteoporos Int"},{"issue":"9","key":"1270_CR36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in US patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929\u201337.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1270_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis: 2016: executive summary. Endocr Pract. 2016;22(9):1111\u20138.","journal-title":"Endocr Pract"},{"issue":"7","key":"1270_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333.","journal-title":"JAMA"},{"issue":"8","key":"1270_CR39","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949\u201357.","journal-title":"J Clin Endocrinol Metab"},{"key":"1270_CR40","unstructured":"NICE. Bisphosphonates for treating osteoporosis. Technology appraisal guidance [TA464]. Last update: 8 July 2019. https:\/\/www.nice.org.uk\/guidance\/ta464. Accessed 14 Apr 2023."},{"issue":"3","key":"1270_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, et al. A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics. 2015;33(3):205\u201324.","journal-title":"Pharmacoeconomics"},{"key":"1270_CR42","unstructured":"IBM. IBM Micromedex Red Book. https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed 1 May 2022."},{"issue":"6","key":"1270_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2017.06.013","volume":"21","author":"J Levy","year":"2018","unstructured":"Levy J, Rosenberg M, Vanness D. A Transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses. Value Health. 2018;21(6):677\u201384.","journal-title":"Value Health"},{"issue":"11","key":"1270_CR44","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","volume":"166","author":"H Liu","year":"2006","unstructured":"Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166(11):1209\u201317.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1270_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11(5):485\u201397.","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"1270_CR46","first-page":"824","volume":"21","author":"LI Cheng","year":"2015","unstructured":"Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, et al. Persistence and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm. 2015;21(9):824\u201333.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"1270_CR47","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020;31(11):2093\u2013102.","journal-title":"Osteoporos Int"},{"issue":"12","key":"1270_CR48","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","volume":"32","author":"AJ Singer","year":"2021","unstructured":"Singer AJ, Liu J, Yan H, Stad RK, Gandra SR, Yehoshua A. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int. 2021;32(12):2473\u201384.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1270_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049.","journal-title":"BMJ Open"},{"issue":"1","key":"1270_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/cer.15.50","volume":"5","author":"R Dubois","year":"2016","unstructured":"Dubois R. Cost-effectiveness thresholds in the USA: are they coming? Are they already here? J Comp Eff Res. 2016;5(1):9\u201311.","journal-title":"J Comp Eff Res."},{"issue":"10","key":"1270_CR51","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","volume":"50","author":"CL Leibson","year":"2002","unstructured":"Leibson CL, Tosteson ANA, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50(10):1644\u201350.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1270_CR52","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/gerona\/glt105","volume":"69","author":"GS Tajeu","year":"2014","unstructured":"Tajeu GS, Delzell E, Smith W, Arora T, Curtis JR, Saag KG, et al. Death, debility, and destitution following hip fracture. J Gerontol A Biol Sci Med Sci. 2014;69(3):346\u201353.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"1270_CR53","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373.","journal-title":"Osteoporos Int"},{"key":"1270_CR54","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"2","key":"1270_CR55","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32(2):198\u2013202.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1270_CR56","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022;34(4):695\u2013714.","journal-title":"Aging Clin Exp Res"},{"key":"1270_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06626-1","author":"G Yu","year":"2022","unstructured":"Yu G, Tong S, Liu J, Wan Y, Wan M, Li S, et al. A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int.\u00a02022;34:641\u201358.\u00a0https:\/\/doi.org\/10.1007\/s00198-022-06626-1.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1270_CR58","first-page":"159","volume":"12","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, Boonen A, Rabenda V, Reginster JY. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharm Out. 2012;12(2):159\u201366.","journal-title":"Expert Rev Pharm Out"},{"issue":"8","key":"1270_CR59","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int. 2022;33(8):1703\u201314.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1270_CR60","doi-asserted-by":"publisher","first-page":"e10457","DOI":"10.1002\/jbm4.10457","volume":"5","author":"DT Gold","year":"2021","unstructured":"Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, et al. Abaloparatide real-world patient experience study. JBMR Plus. 2021;5(3):e10457.","journal-title":"JBMR Plus"},{"issue":"1","key":"1270_CR61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bone.2012.11.018","volume":"53","author":"JM Kaufman","year":"2013","unstructured":"Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, et al. Treatment of osteoporosis in men. Bone. 2013;53(1):134\u201344.","journal-title":"Bone"},{"issue":"6","key":"1270_CR62","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40520-021-01845-8","volume":"33","author":"JM Kaufman","year":"2021","unstructured":"Kaufman JM. Management of osteoporosis in older men. Aging Clin Exp Res. 2021;33(6):1439\u201352.","journal-title":"Aging Clin Exp Res"},{"issue":"12","key":"1270_CR63","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018;29(12):2623\u201337.","journal-title":"Osteoporos Int"},{"issue":"7","key":"1270_CR64","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00198-020-05765-7","volume":"32","author":"E Soreskog","year":"2021","unstructured":"Soreskog E, Borgstrom F, Lindberg I, Strom O, Willems D, Libanati C, et al. A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Osteoporos Int. 2021;32(7):1301\u201311.","journal-title":"Osteoporos Int"},{"issue":"11","key":"1270_CR65","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/jbmr.1684","volume":"27","author":"NC Wright","year":"2012","unstructured":"Wright NC, Saag KG, Curtis JR, Smith WK, Kilgore ML, Morrisey MA, et al. Recent trends in hip fracture rates by race\/ethnicity among older US adults. J Bone Miner Res. 2012;27(11):2325\u201332.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1270_CR66","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380\u201390.","journal-title":"Ann Intern Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01270-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:49:02Z","timestamp":1729298942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01270-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01270-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]},"assertion":[{"value":"19 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is sponsored by Radius Health, Inc. The sponsor was involved in the design of the study, review of the protocol, and review and author approval of the manuscript. The sponsor had no role in the final selection of data and assumptions, execution and analysis of the model, and the interpretation of the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Micka\u00ebl Hiligsmann has received research grants through his institution from Amgen, Radius Health, and ViiV, consulting fees from UCB and lecture fees from Mylan Pharmaceuticals; Stuart S. Silverman has received grants from Amgen and Radius\u00a0Health and consulting fees from Amgen and Radius Health. Andrea J. Singer has received research grants paid to her institution from Radius Health and UCB, consulting fees from Agnovos, Amgen, Radius Health, and UCB, and speaking fees from Amgen and Radius Health. Jake Mathew, Yamei Wang, Leny Pearman, and John Caminis are employees and shareholders in Radius Health. Jean-Yves Reginster has received consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, and Teva; lecture fees when speaking at the invitation of a sponsor: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council, Teva; and grant support from industry (all through institution) from IBSA-Genevrier, Mylan, CNIEL, and Radius Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data utilized in this study are included in this published article (and its supplementary information files).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept and design: MH and JYR; protocol review and approval: all authors; acquisition of data: MH and JYR; model analyses: MH and JYR; interpretation of data: MH, SS, AS, JYR; critical revision of the paper for important intellectual content: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}